Christoph Freiberg

Summary

Affiliation: Bayer HealthCare AG
Country: Germany

Publications

  1. ncbi Novel whole-cell antibiotic biosensors for compound discovery
    Andreas Urban
    Pharma Research and Development, Discovery Europe, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    Appl Environ Microbiol 73:6436-43. 2007
  2. ncbi Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity
    Christoph Freiberg
    Institute of Anti infectives Research, Institute of Chemistry Research, and Institute of Cardiovascular Research, Pharma Research, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    J Biol Chem 279:26066-73. 2004
  3. ncbi Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action
    Jens Pohlmann
    Department of Medicinal Chemistry, Bayer HealthCare AG, D-42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:1189-92. 2005
  4. ncbi Discovering antibiotic efficacy biomarkers: toward mechanism-specific high content compound screening
    Christoph Freiberg
    Pharma Global Drug Discovery, European Research Center, Bayer HealthCare AG, D-42096 Wuppertal, Germany
    Mol Cell Proteomics 5:2326-35. 2006
  5. ncbi Total synthesis and initial structure-activity relationships of longicatenamycin A
    Franz von Nussbaum
    Bayer HealthCare, Global Drug Discovery, 42096 Wuppertal, Germany
    ChemMedChem 3:619-26. 2008
  6. ncbi Functional genomics in antibacterial drug discovery
    Christoph Freiberg
    Bayer HealthCare AG, Antibacterial Research, 42096 Wuppertal, Germany
    Drug Discov Today 10:927-35. 2005
  7. ncbi The impact of transcriptome and proteome analyses on antibiotic drug discovery
    Christoph Freiberg
    Antibacterial Research (PH-R-EU-AI, Bayer HealthCare AG, 42096 Wuppertal, Germany
    Curr Opin Microbiol 7:451-9. 2004
  8. ncbi The role of peptide deformylase in protein biosynthesis: a proteomic study
    Julia Elisabeth Bandow
    Institut fur Mikrobiologie, Ernst Moritz Arndt Universitat, Greifswald, Germany
    Proteomics 3:299-306. 2003
  9. ncbi Prediction of mechanisms of action of antibacterial compounds by gene expression profiling
    Bernd Hutter
    GPC Biotech AG, Microbiology, Munich, Germany
    Antimicrob Agents Chemother 48:2838-44. 2004
  10. ncbi Applications of transcriptional profiling in antibiotics discovery and development
    Hans Peter Fischer
    Genedata AG, Postfach 254, 4016 Basel, Switzerland
    Prog Drug Res 64:21, 23-47. 2007

Collaborators

Detail Information

Publications12

  1. ncbi Novel whole-cell antibiotic biosensors for compound discovery
    Andreas Urban
    Pharma Research and Development, Discovery Europe, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    Appl Environ Microbiol 73:6436-43. 2007
    ..For instance, we show that the mechanistically underexplored antibiotic ferrimycin A1 selectively inhibits protein biosynthesis...
  2. ncbi Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity
    Christoph Freiberg
    Institute of Anti infectives Research, Institute of Chemistry Research, and Institute of Cardiovascular Research, Pharma Research, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    J Biol Chem 279:26066-73. 2004
    ....
  3. ncbi Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action
    Jens Pohlmann
    Department of Medicinal Chemistry, Bayer HealthCare AG, D-42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:1189-92. 2005
    ....
  4. ncbi Discovering antibiotic efficacy biomarkers: toward mechanism-specific high content compound screening
    Christoph Freiberg
    Pharma Global Drug Discovery, European Research Center, Bayer HealthCare AG, D-42096 Wuppertal, Germany
    Mol Cell Proteomics 5:2326-35. 2006
    ..The general approach is also applicable to drug discovery for medical indications other than infectious diseases...
  5. ncbi Total synthesis and initial structure-activity relationships of longicatenamycin A
    Franz von Nussbaum
    Bayer HealthCare, Global Drug Discovery, 42096 Wuppertal, Germany
    ChemMedChem 3:619-26. 2008
    ..This first total synthesis of longicatenamycin A provided new congeners of the natural product (deacetyllongicatenamycin, dechlorolongicatenamycin, and longicatenamycin-A-amide)...
  6. ncbi Functional genomics in antibacterial drug discovery
    Christoph Freiberg
    Bayer HealthCare AG, Antibacterial Research, 42096 Wuppertal, Germany
    Drug Discov Today 10:927-35. 2005
    ..Functional genomics supports antibacterial drug discovery by improving knowledge on gene function, bacterial physiology and virulence and the effects of antibiotics on bacterial metabolism...
  7. ncbi The impact of transcriptome and proteome analyses on antibiotic drug discovery
    Christoph Freiberg
    Antibacterial Research (PH-R-EU-AI, Bayer HealthCare AG, 42096 Wuppertal, Germany
    Curr Opin Microbiol 7:451-9. 2004
    ..In addition, such compendia open up ways for novel cell-based drug screening approaches...
  8. ncbi The role of peptide deformylase in protein biosynthesis: a proteomic study
    Julia Elisabeth Bandow
    Institut fur Mikrobiologie, Ernst Moritz Arndt Universitat, Greifswald, Germany
    Proteomics 3:299-306. 2003
    ..Eight of these protein pairs were also present on 2-D gels of exponentially growing B. subtilis, where the more acidic, still formylated protein species represented the smaller parts...
  9. ncbi Prediction of mechanisms of action of antibacterial compounds by gene expression profiling
    Bernd Hutter
    GPC Biotech AG, Microbiology, Munich, Germany
    Antimicrob Agents Chemother 48:2838-44. 2004
    ..A database of this kind may facilitate the prioritization of novel antibacterial entities in drug discovery programs. Potential applications and limitations are discussed...
  10. ncbi Applications of transcriptional profiling in antibiotics discovery and development
    Hans Peter Fischer
    Genedata AG, Postfach 254, 4016 Basel, Switzerland
    Prog Drug Res 64:21, 23-47. 2007
    ..Microarrays will continue to be a workhorse of anti-infectives discovery programs ranging from efficacy assessments of antibiotics ('forward pharmacology') to drug safety evaluations ('toxicogenomics')...
  11. ncbi Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery
    Hans Peter Fischer
    Genedata AG, Postfach 254, CH 4016, Basel, Switzerland
    Genome Res 14:90-8. 2004
    ..In a proof-of-principle experiment, this assay was shown to enable screening for new small-molecule inhibitors of bacterial growth...
  12. ncbi Staphylococcus aureus NfrA (SA0367) is a flavin mononucleotide-dependent NADPH oxidase involved in oxidative stress response
    Karin Streker
    Institut für Molekulare Infektionsbiologie, Rontgenring 11, D 97070 Wurzburg, Germany
    J Bacteriol 187:2249-56. 2005
    ..The observations presented here suggest that NfrA is a nonessential NADPH oxidoreductase which may play a role in the oxidative stress response of S. aureus, especially in keeping thiol-disulfide stress in balance...